Literature DB >> 20095039

Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.

Jungwon Huh1, Ramon V Tiu, Lukasz P Gondek, Christine L O'Keefe, Monika Jasek, Hideki Makishima, Ania M Jankowska, Ying Jiang, Amit Verma, Karl S Theil, Michael A McDevitt, Jaroslaw P Maciejewski.   

Abstract

Deletion of the long arm of chromosome 20 is a common abnormality associated with myeloid malignancies. We characterized abnormalities of chromosome 20 as defined by metaphase cytogenetics (MC) in patients with myeloid neoplasms to define commonly deleted regions (CDR) and commonly retained regions (CRR) using genome-wide, high resolution single nucleotide polymorphism array (SNP-A) analysis. We reviewed the MC results of a cohort of 1,162 patients with myeloid malignancies, including myelodysplastic syndromes (MDS), MDS/myeloproliferative neoplasia (MDS/MPN), and acute myeloid leukemia (AML). We further analyzed a subcohort of 532 patients by SNP-A using the Affymetrix Genome-Wide Human SNP Array 6.0 and GeneChip Human Mapping 250K Nsp arrays. By MC, 5% (54/1,162) harbored a deletion of 20q; in 30% (16/54), del(20q) was the sole cytogenetic abnormality. By SNP-A analysis, we identified del(20q) in 23 patients, 3 not detected by MC. In four cases, monosomy 20 with a marker chromosome by MC was proven to be an interstitial deletion of 20q by SNP-A. We defined 2 CDR and 2 CRR on chromosome arm 20q: CDR1 spanned 2.5 Mb between bands 20q11.23 and 20q12, while CDR2 encompassed 1.8 Mb within 20q13.12. CRR1 spanned 1.9 Mb within 20q11.21 and CRR2 encompassed 2.5 Mb within 20q13.33. In contrast to other chromosomes frequently affected by deletions, no somatic copy neutral loss of heterozygosity (CN-LOH) was detected. Our data suggest that SNP-A is useful for the detection of cryptic aberrations of chromosome 20q and allows for a more precise characterization of complex karyotypes. Furthermore, SNP-A allowed definition of a CDR on 20q.

Entities:  

Mesh:

Year:  2010        PMID: 20095039     DOI: 10.1002/gcc.20748

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  24 in total

1.  Microarray CGH analysis of hematological patients with del(20q).

Authors:  Chunxiao Wu; Jinlan Pan; Huiying Qiu; Yongquan Xue; Suning Chen; Yafang Wu; Jun zhang; Shuxiao Bai; Yong Wang; Juan Shen; Yanlei Gong
Journal:  Int J Hematol       Date:  2015-10-06       Impact factor: 2.490

2.  Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.

Authors:  C Cameron Yin; Jie Peng; Yu Li; Rashmi Kanagal-Shamanna; Tariq Muzzafar; Courtney DiNardo; Joseph D Khoury; Shaoying Li; L Jeffrey Medeiros; Sa A Wang; Guilin Tang
Journal:  Mod Pathol       Date:  2015-06-05       Impact factor: 7.842

3.  Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

Authors:  Andres Jerez; Lukasz P Gondek; Anna M Jankowska; Hideki Makishima; Bartlomiej Przychodzen; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Denise Batista; Mikkael A Sekeres; Michael A McDevitt; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

4.  Mosaic chromosome 20q deletions are more frequent in the aging population.

Authors:  Mitchell J Machiela; Weiyin Zhou; Neil Caporaso; Michael Dean; Susan M Gapstur; Lynn Goldin; Nathaniel Rothman; Victoria L Stevens; Meredith Yeager; Stephen J Chanock
Journal:  Blood Adv       Date:  2017-02-13

5.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Authors:  Brady L Stein; Donna M Williams; Christine O'Keefe; Ophelia Rogers; Roxann G Ingersoll; Jerry L Spivak; Amit Verma; Jarek P Maciejewski; Michael A McDevitt; Alison R Moliterno
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

Review 6.  CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.

Authors:  Ming-Chung Jiang
Journal:  Tumour Biol       Date:  2016-09-05

Review 7.  An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.

Authors:  Lucy A Godley; John Cunningham; M Eileen Dolan; R Stephanie Huang; Sandeep Gurbuxani; Megan E McNerney; Richard A Larson; Hoyee Leong; Yves Lussier; Kenan Onel; Olatoyosi Odenike; Wendy Stock; Kevin P White; Michelle M Le Beau
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

Review 8.  Mutations in epigenetic regulators in myelodysplastic syndromes.

Authors:  Gorica Nikoloski; Bert A van der Reijden; Joop H Jansen
Journal:  Int J Hematol       Date:  2012-01-11       Impact factor: 2.490

9.  Dynamics of clonal evolution in myelodysplastic syndromes.

Authors:  Hideki Makishima; Tetsuichi Yoshizato; Kenichi Yoshida; Mikkael A Sekeres; Tomas Radivoyevitch; Hiromichi Suzuki; Bartlomiej Przychodzen; Yasunobu Nagata; Manja Meggendorfer; Masashi Sanada; Yusuke Okuno; Cassandra Hirsch; Teodora Kuzmanovic; Yusuke Sato; Aiko Sato-Otsubo; Thomas LaFramboise; Naoko Hosono; Yuichi Shiraishi; Kenichi Chiba; Claudia Haferlach; Wolfgang Kern; Hiroko Tanaka; Yusuke Shiozawa; Inés Gómez-Seguí; Holleh D Husseinzadeh; Swapna Thota; Kathryn M Guinta; Brittney Dienes; Tsuyoshi Nakamaki; Shuichi Miyawaki; Yogen Saunthararajah; Shigeru Chiba; Satoru Miyano; Lee-Yung Shih; Torsten Haferlach; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Nat Genet       Date:  2016-12-19       Impact factor: 38.330

10.  Deletion of Ptpn1 induces myeloproliferative neoplasm.

Authors:  F Jobe; B Patel; T Kuzmanovic; H Makishima; Y Yang; B Przychodzen; R E Hutchison; K K Bence; J P Maciejewski; G Mohi
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.